Comparison

Recombinant Hepatitis B Virus Core Antigen (a.a. 184)

Item no. DAG556
Manufacturer Creative Diagnostics
Amount 100 ug
Category
Type Proteins Recombinant
Format Liquid
Applications ELISA
Specific against other
Purity ca.95%, pure (SDS-PAGE). Repetitive chromatography
ECLASS 10.1 32160409
ECLASS 11.0 32160409
UNSPSC 12352202
Available
Manufacturer - Applications
Suitable, for use in ELISA and Western blot. Each laboratory should determine an, optimum working titer for use in its particular application. Other, applications have not been tested but use in such assays should not necessarily, be excluded.
Storage Conditions
Aliquot, and store at -20°C. Avoid multiple freeze/thaw cycles.
Full name
Hepatitis B Virus Core Antigen
Product Overview
Recombinant, Hepatitis B Virus Core Antigen, full length core, protein(a.a 184), does not contain fusion partner, was, expressed in E. coli, and puried in vitro using conventional chromatography, techniques.
Background - Introduction
Hepatitis B virus, abbreviated HBV, is a species of the genus Orthohepadnavirus, which is, likewise a part of the Hepadnaviridae family of viruses. This virus causes, the disease hepatitis B.
Background - Keywords
Hepatitis B Core Ag, Hepatitis B Core Antigen, HBcAg, Hepatitis B Virus Core Antigen, Hepatitis B, virus, HBV, Core antigen, C, Capsid protein, Core protein, HBc, p21.5, Hepadnaviridae, Orthohepadnavirus
Abbr
HBcAg (a.a. 184)
Manufacturer - Format
Purified, Liquid
Buffer
50mM, Tris, 1mM EDTA, 150mM Sodium Chloride, pH 7.5
Concentration
0.85mg/ml, (OD280nm, E1% = 14)
Preservative
None
Antigen Description
Hepatitis B Virus, Core Antigen (HBcAg) is part of the infectious virion containing an inner, core particle enclosing the viral genome. The icosahedral core, particle contains 180 or 240 copies of the core protein. HBcAg is one of the, three major clinical antigens of hepatitis B virus but disappears early in, the course of infection. The hepatitis B virus core antigen (HBcAg) is a, highly immunogenic subviral particle and functions as both a T-cell-dependent, and a T-cell-independent antigen. Therefore, HBcAg may be a promising, candidate target for therapeutic vaccine control of chronic HBV infection.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 100 ug
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close